Vanguard Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$97.9M Buy
4,754,495
+177,635
+4% +$3.79M ﹤0.01% 1539
2026
Q2
$84.1M Buy
4,576,860
+409,659
+10% +$6.6M ﹤0.01% 1652
2026
Q1
$81.5M Buy
+4,167,201
New +$124M ﹤0.01% 1582

Other funds holding VRDN

Vanguard Capital Management's VRDN Position: Q3 2026 in Review

Vanguard Capital Management increased its Viridian Therapeutics (VRDN) stake by 3.9% in Q3 2026, buying an estimated $3.79M and bringing the position to 4,754,495 shares worth $97.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1539.

Vanguard Capital Management first reported a position in VRDN in Q1 2026 and has held it in 3 quarters since. 235 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.

  • Vanguard Capital Management held 4,754,495 shares of Viridian Therapeutics worth $97.9M as of Q3 2026.
  • Vanguard Capital Management bought 177,635 Viridian Therapeutics shares in Q3 2026, an estimated $3.79M.
  • Viridian Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1539 holding.
  • Vanguard Capital Management first reported a position in Viridian Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 235 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.